Research programme: influenza vaccines - Medicago
Alternative Names: Pandemic influenza virus vaccines - Medicago; Plant-based VLP vaccines - Medicago; Seasonal influenza virus vaccines - Medicago; Virus-like particle vaccines - MedicagoLatest Information Update: 23 Jul 2019
Price :
$50 *
At a glance
- Originator Medicago
- Class Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Canada (Parenteral)
- 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
- 11 Dec 2012 Medicago receives grant from National Research Council of Canada for Influenza VLP vaccine candidate development